1. Home
  2. OWLT vs CBIO Comparison

OWLT vs CBIO Comparison

Compare OWLT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Owlet Inc.

OWLT

Owlet Inc.

N/A

Current Price

$6.30

Market Cap

318.6M

Sector

Health Care

ML Signal

N/A

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.10

Market Cap

389.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OWLT
CBIO
Founded
2013
2003
Country
United States
United States
Employees
85
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.6M
389.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OWLT
CBIO
Price
$6.30
$12.10
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$20.00
$26.67
AVG Volume (30 Days)
294.3K
170.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$37.02
N/A
Revenue Next Year
$22.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$8.72
52 Week High
$16.94
$17.39

Technical Indicators

Market Signals
Indicator
OWLT
CBIO
Relative Strength Index (RSI) 21.51 57.95
Support Level N/A $11.88
Resistance Level $8.78 $13.37
Average True Range (ATR) 0.80 0.99
MACD -0.36 0.12
Stochastic Oscillator 3.68 66.35

Price Performance

Historical Comparison
OWLT
CBIO

About OWLT Owlet Inc.

Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: